Hoboken, NJ — July 15, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease (AD) currently in Phase I clinical trials, will be presented in two poster sessions at the 2011 Alzheimer’s Association International Conference on Alzheimer’s Disease (AAICAD) in…

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved